Connor, Clark & Lunn Investment Management Ltd. Atossa Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $26 Billion
- Q2 2025
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Atossa Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 198,668 shares of ATOS stock, worth $156,947. This represents 0.0% of its overall portfolio holdings.
Number of Shares
198,668
Previous 189,319
4.94%
Holding current value
$156,947
Previous $126,000
30.16%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ATOS
# of Institutions
82Shares Held
26.5MCall Options Held
63.6KPut Options Held
53.2K-
Black Rock Inc. New York, NY9.2MShares$7.27 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.59MShares$5.2 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.86MShares$1.47 Million0.0% of portfolio
-
State Street Corp Boston, MA1.73MShares$1.36 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.3MShares$1.03 Million0.0% of portfolio
About ATOSSA THERAPEUTICS, INC.
- Ticker ATOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,624,000
- Market Cap $100M
- Description
- Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing A...